NEW YORK , Aug. 13, 2024 /PRNewswire/ -- The global prefilled syringes market size is estimated to grow by USD 4.04 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of almost 9.45% during the forecast period. Favorable regulations and guidelines is driving market growth, with a trend towards increasing number of approval of biologics.
However, competition from alternative drug delivery systems poses a challenge. Key market players include Ajinomoto Bio Pharma Services, ApiJect Systems Corp., AptarGroup Inc.
, Baxter International Inc., Becton Dickinson and Co., Catalent Inc.
, Fresenius SE and Co. KGaA, Gerresheimer AG, Haselmeier GmbH, Nipro Corp., Novartis AG, Owen Mumford Ltd.
, Recipharm AB, SCHOTT AG , SHL Medical AG, STERINOVA, Terumo Corp., Vetter Pharma Fertigung GmbH and Co. KG, Viatris Inc.
, and West Pharmaceutical Services Inc.. Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report Market Driver The pharmaceutical industry's shift from small-molecule chemical drugs to large-molecule biologics has led to significant advancements in treating chronic diseases such as diabetes, multiple sclerosis, and rheumatoid arthritis.
In 2022, the FDA approved 37 new drugs and 15 biologics. Pre-filled syringes offer advantages like material and cost savings, accuracy, and ease of administration, making them an ideal choice for packaging and delivering biological products. Of th.